Keith Goldan Sells 2,082 Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith Goldan sold 2,082 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $20.62, for a total transaction of $42,930.84. Following the transaction, the chief financial officer directly owned 143,839 shares of the company’s stock, valued at $2,965,960.18. This trade represents a 1.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Syndax Pharmaceuticals Trading Up 4.3%

Shares of SNDX stock opened at $21.01 on Friday. The company has a current ratio of 4.64, a quick ratio of 4.42 and a debt-to-equity ratio of 2.78. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -5.82 and a beta of 0.46. Syndax Pharmaceuticals, Inc. has a 12-month low of $8.58 and a 12-month high of $22.73. The stock’s 50-day moving average price is $20.67 and its 200-day moving average price is $17.02.

Institutional Trading of Syndax Pharmaceuticals

A number of large investors have recently modified their holdings of SNDX. Phoenix Financial Ltd. bought a new position in shares of Syndax Pharmaceuticals in the 2nd quarter worth $701,000. Sector Gamma AS bought a new position in Syndax Pharmaceuticals in the third quarter worth about $3,243,000. Franklin Resources Inc. lifted its position in shares of Syndax Pharmaceuticals by 14.5% during the second quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company’s stock valued at $22,098,000 after buying an additional 298,272 shares during the last quarter. Aberdeen Group plc boosted its holdings in shares of Syndax Pharmaceuticals by 129.1% in the 2nd quarter. Aberdeen Group plc now owns 303,426 shares of the company’s stock valued at $2,842,000 after buying an additional 170,993 shares in the last quarter. Finally, Schroder Investment Management Group grew its position in shares of Syndax Pharmaceuticals by 112.2% in the 2nd quarter. Schroder Investment Management Group now owns 122,163 shares of the company’s stock worth $1,144,000 after buying an additional 64,598 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $56.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 9th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Syndax Pharmaceuticals in a research report on Monday, October 27th. UBS Group raised their price objective on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Wall Street Zen upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $37.20.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.